Banco Bilbao Vizcaya Argentaria S.A. Has $27.83 Million Position in Regeneron Pharmaceuticals, Inc. $REGN

Banco Bilbao Vizcaya Argentaria S.A. lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 36,038 shares of the biopharmaceutical company’s stock after selling 1,587 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Regeneron Pharmaceuticals were worth $27,833,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock valued at $7,004,838,000 after buying an additional 26,884 shares in the last quarter. Dodge & Cox lifted its holdings in Regeneron Pharmaceuticals by 1.0% during the fourth quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock worth $3,547,791,000 after acquiring an additional 45,513 shares in the last quarter. Franklin Resources Inc. grew its stake in Regeneron Pharmaceuticals by 4.4% in the fourth quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock valued at $1,975,990,000 after acquiring an additional 106,861 shares during the period. Nuveen LLC grew its stake in Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after acquiring an additional 835,240 shares during the period. Finally, Capital World Investors increased its holdings in shares of Regeneron Pharmaceuticals by 1.6% in the third quarter. Capital World Investors now owns 1,998,366 shares of the biopharmaceutical company’s stock worth $1,123,609,000 after acquiring an additional 32,348 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the sale, the director directly owned 17,503 shares of the company’s stock, valued at $12,343,815.72. The trade was a 0.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Stock Down 1.1%

Shares of Regeneron Pharmaceuticals stock opened at $607.93 on Thursday. The firm has a market cap of $64.27 billion, a PE ratio of 14.81, a P/E/G ratio of 1.35 and a beta of 0.25. The business’s 50 day simple moving average is $683.13 and its 200 day simple moving average is $734.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. Regeneron Pharmaceuticals, Inc. has a 52-week low of $503.25 and a 52-week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business’s quarterly revenue was up 19.0% on a year-over-year basis. During the same period last year, the business earned $8.22 EPS. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.44 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were paid a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on REGN. Barclays cut their price objective on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. Morgan Stanley lifted their price target on shares of Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. TD Cowen upped their price target on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. Finally, Royal Bank Of Canada lowered their price objective on shares of Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating for the company in a research report on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $792.65.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.